Sutro Biopharma is a clinical-stage oncology company developing site-specific and antibody drug conjugates (ADCs) enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF®, and its site-specific conjugation platform, XpressCF+®. Co.'s product candidate is STRO-002, or luveltamab tazevibulin, an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. Co.'s other product candidate is STRO-001, an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Co. also has a preclinical product candidate, STRO-003, which is a single homogeneous ADC. We show 27 historical shares outstanding datapoints in our STRO shares outstanding history coverage, used to compute STRO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing STRO market cap history over the course of time is important for investors
interested in comparing STRO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of STRO versus a peer is one thing; comparing
STRO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like STRO can fluctuate over the course of history.
With this page we aim to empower investors researching STRO by allowing them to research the STRO market cap history. |
Free STRO Email Alerts:
Video: The Importance of Market Cap
